DiaMedica Therapeutics (DMAC) Short term Debt (2017)
DiaMedica Therapeutics (DMAC) reported Short term Debt of $84000.0 for Q4 2017.
DiaMedica Therapeutics (DMAC) Short term Debt (2017) Analysis & Trends
DiaMedica Therapeutics has reported Short term Debt for 1 years, with the latest figure at $84000.0 in Q4 2017.
- For the quarter ending Q4 2017, Short term Debt changed N/A year-over-year to $84000.0; the trailing twelve-month figure through Dec 2017 stood at $84000.0 (changed N/A YoY), and the FY2017 full-year result was $84000.0, changed N/A from the prior year.
- Short term Debt for Q4 2017 stood at $84000.0.
- The five-year high for Short term Debt was $84000.0 in Q4 2017, with the low at $84000.0 in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | DiaMedica Therapeutics | 285.11 Mn | 233.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 84,000.00 |